# Feasibility Assessment: Organelle-Specific Autophagy Selectivity in Neurodegeneration
---
## Overview
Both hypotheses survive the skeptic's critique sufficiently to warrant continued experimental testing, but with significant revisions. Neither represents a near-term therapeutic target as originally framed. The path forward requires decoupling the speculative therapeutic claim from the legitimate mechanistic question.
---
## Hypothesis 1: Calcineurin-FUNDC1 Axis
### Druggability
**Calcineurin (PPP3CA):** High tractability historically — FK506 and cyclosporine A are FDA-approved with well-characterized binding interfaces (calcineurin A/B heterodimer with distinct cyclophilin complex). However, this creates a *liability*, not an asset, for neurodegeneration: these drugs are immunosuppressants whose systemic and renal toxicity profiles make them clinically unacceptable for chronic CNS use. Development of CNS-selective calcineurin modulators would require substantial medicinal chemistry investment. **Near-term: viable only as a tool compound, not a therapeutic.**
**FUNDC1:** Low tractability. No established small-molecule modulators exist; the protein structure is not crystallized; and it remains poorly characterized compared to PINK1/Parkin. Deorphanizing FUNDC1 as a therapeutic target requires foundational work before any drug discovery program is credible.
**Critical bottleneck:** Even if calcineurin inhibition suppresses apoptosis in vitro, you cannot selectively inhibit calcineurin in neurons without systemic immunosuppression. The FK506 therapeutic window in neurodegeneration is effectively zero.
### Biomarkers
- FUNDC1 S13 phosphorylation is detectable by phospho-specific immunoblot but has no approved clinical assay
- Peripheral blood mononuclear cell (PBMC) calcineurin activity has been used in transplant studies — could serve as a pharmacodynamic marker
- Mitochondrial respiration (Seahorse XF) in patient-derived iPSC neurons is feasible but costly and not standardized
- **No validated fluid biomarker** for the proposed axis exists, which would be required for Phase II efficacy readouts
### Model Systems
**Strengths:** Primary rodent neurons + mitochondrial stress is mechanistically tractable and widely used.
**Weaknesses:**
- PINK1/Park2 KO backgrounds are doubly confounded for mitophagy — a cleaner test uses wild-type neurons under selective lysosomal inhibition (bafilomycin A1) to isolate the FUNDC1-lysosomal interface
- Mouse models of neurodegeneration do not recapitulate human neuronal lysosomal failure faithfully; the disease-relevant lysosomal state is not reliably modeled
- Human iPSC-derived neurons are more translational but lack the aged proteostatic collapse that characterizes AD/PD
### Clinical Development Constraints
1. **Blood-brain barrier penetration** is a tier-1 obstacle for both calcineurin inhibitors and any FUNDC1-directed agent
2. **Immunosuppression risk** disqualifies systemic calcineurin inhibitors from chronic neurodegeneration use; a topical or CNS-restricted delivery mechanism has no current precedent
3. **Target validation gap:** No human genetic evidence links FUNDC1 to AD or PD — the hypothesis is mechanistically inferred, not genetically anchored
4. **Indication selection:** If the mechanism truly differentiates mitophagy from apoptosis, it would apply broadly; limiting to a specific indication (e.g., PINK1-linked PD) would improve signal detection but dramatically narrow commercial viability
### Safety
- FK506 nephrotoxicity, neurotoxicity, and metabolic syndrome are well-characterized and would be unacceptable for an elderly neurodegenerative population
- Tighter therapeutic index than any CNS drug on market — the risk/benefit calculation fails unless efficacy is dramatic
- No safety data exist for FUNDC1 modulation of any kind
### Timeline and Cost
| Stage | Estimate |
|---|---|
| Target validation + lead identification | 4–6 years, $80–120M |
| Lead optimization + BBB optimization | 5–7 years, $150–300M |
| IND-enabling + Phase I | 3–4 years, $100–200M |
| **Total to Phase II read-out** | **12–17 years, $400–600M+** |
No fast-follower advantage exists because the target is early-stage. This is a discovery-phase investment, not a near-term therapeutic bet.
---
## Hypothesis 2: TREM2-GSK3β-p62 Axis
### Druggability
**TREM2:** High tractability — monoclonal antibodies (AL002, RG6333) are already in Phase I/II for Alzheimer's disease (NCT04128558, NCT04638855). This is the most druggable element of either hypothesis. Genetic validation is strong (TREM2 loss-of-function mutations increase AD risk ~2–4 fold).
**Syk kinase:** Fostamatinib is FDA-approved for ITP; moderate tractability but limited BBB penetration — a significant constraint for neurodegeneration.
**GSK3β:** High tractability historically — dozens of inhibitors in clinical trials for AD, diabetes, and oncology. However, every GSK3β inhibitor